thymoglobulin + sirolimus + mycophenolate mofetil

A multi-drug immunosuppressive regimen combining Thymoglobulin, sirolimus, and mycophenolate mofetil used primarily in solid organ transplantation for induction and maintenance of immunosuppression. Thymoglobulin is rabbit anti-thymocyte globulin, a polyclonal antibody preparation that depletes circulating T cells and modulates immune activation pathways. Sirolimus (rapamycin) is an mTOR inhibitor that blocks IL-2-driven T-cell proliferation and inhibits mTORC1-mediated cell-cycle progression. Mycophenolate mofetil is a prodrug of mycophenolic acid, which inhibits inosine monophosphate dehydrogenase to block de novo guanine nucleotide synthesis, selectively suppressing proliferation of T and B lymphocytes. Together, the combination provides complementary mechanisms: rapid lymphocyte depletion and immunomodulation (Thymoglobulin), signal transduction blockade of lymphocyte proliferation (sirolimus), and antiproliferative inhibition of nucleotide synthesis (mycophenolate), aiming to prevent acute rejection and support graft survival.

Other names

rATG + sirolimus + MMF